Atovaquone
RxNorm 60212
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 60212 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Atovaquone.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
INPrescribable
Ingredient (IN):
Atovaquone
(Atom ID: 12252856)
PTPrescribable
Designated preferred name (PT):
Atovaquone
(Atom ID: 556717)
FNPrescribable
Full form of descriptor (FN):
Atovaquone (substance)
(Atom ID: 556724)
PTPrescribable
Designated preferred name (PT):
Atovaquone-containing product
(Atom ID: 10797270)
FNPrescribable
Full form of descriptor (FN):
Product containing atovaquone (medicinal product)
(Atom ID: 9254007)
Patient Education
Atovaquone
Atovaquone is used to treat Pneumocystis jiroveci [Pneumocystis carinii] pneumonia (PCP; type of pneumonia most likely to affect people with human immunodeficiency virus [HIV]) in teenagers and adults. Atovaquone is also used to prevent PCP in teenagers and adults who cannot take another medication used for prevention. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia.
[Learn More]
* Please review the disclaimer below.